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INVITED REVIEW ABSTRACT: Myotonic dystrophy types 1 (DM1) and 2 (DM2) are similar
yet distinct autosomal-dominant disorders characterized by muscle weak-
ness, myotonia, cataracts, and multiple organ involvement, including the
brain. One key difference between DM1 and DM2 is that a congenital form
has been described for DM1 only. Expression of RNA transcripts containing
pathogenic repeat lengths produces defects in alternative splicing of multiple
RNAs, sequesters speciﬁc repeat-binding proteins, and ultimately leads to
developmentally inappropriate splice products for a particular tissue.
Whether brain pathology in its entirety in adult DM1 and DM2 is caused by
interference in RNA processing remains to be determined. This review
focuses on the similarities and differences between DM1 and DM2 with
respect to neuropsychological, neuropathological, and neuroimaging data
relating to cerebral involvement, with special emphasis on the clinical rele-
vance and social consequences of such involvement.
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Myotonic dystrophies, the most common type of
adult-onset muscular dystrophy, are dominantly in-
herited disorders characterized by muscle weakness
and atrophy, myotonia, and cataracts, together with
involvement of a number of different organs, includ-
ing the brain.4,41 Myotonic dystrophy type 1 (DM1) is
caused by an expanded (CTG)n repeat (from 37 to
several thousands) within the noncoding 3 untrans-
lated region of the myotonic dystrophy protein ki-
nase (DMPK) gene9,35,61 on chromosome 19q35.
Myotonic dystrophy type 2 (DM2) is caused by an
expanded CCTG repeat (from 75 to 11,000 repeats)
in the ﬁrst intron of the zinc ﬁnger protein 9 (ZNF9)
gene on chromosome 3q21.25,60,95,96
Fascinating aspects of the myotonic dystrophies
are the multisystem involvement and the way that
two unrelated genes cause strikingly similar yet dis-
tinct phenotypes. Both DM1 and DM2 manifest signs
of myotonia, muscle weakness, and early-onset cata-
racts. In addition, there is often testicular atrophy,
frontal balding, insulin resistance, and cardiac con-
duction defects, as well as occasionally dilated car-
diomyopathy.41,70,97 There is, however, one key clin-
ical difference between DM1 and DM2: the degree
of cognitive impairment. The DM1 locus presents a
severe congenital form of mental retardation, which
is not present in DM2. In addition, whereas person-
ality changes, visual-spatial defects, and behavioral
problems have been described mainly in the juvenile
and adult-onset forms of DM1, it is only in the last
few years that there have been reports of cognitive
and behavioral deﬁcits in DM2, and these may be
captured only by speciﬁc neuropsychological tests.
Considering these results and the absence of a con-
genital form, there is still controversy as to the clin-
ical signiﬁcance of the cognitive and behavioral ab-
normalities reported in patients with DM2.
Recent advances in molecular genetics in
vitro and using mouse models have shed light
on the pathophysiology of myotonic dystro-
phies.8,17,44,54,59,63,64,66,83,89,94,116–119 The current
model is that expression of RNA transcripts con-
taining pathogenic repeat lengths produces de-
fects in alternative splicing of multiple RNAs by
sequestering repeat-binding proteins, ultimately
leading to the expression of splice products that
are developmentally inappropriate for a particular
tissue. This provides a fascinating rationale for
many of the multisystem features of DM1 and
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DM2, including cerebral symptoms, but in-depth
studies are still lacking. Caution is required when
interpreting the results of such studies. There are
still a number of open issues regarding DM1, and
particularly DM2, concerning brain involvement.
(1) Although likely, an abnormality in the alterna-
tive splicing of tau, amyloid precursor protein
(APP), and the like in DM2 brains is yet to be
demonstrated. Whether brain involvement in
adult DM1 and DM2 is caused entirely by interfer-
ence in RNA processing remains to be deter-
mined. Convincing evidence on a molecular level
is still missing, although there are suggestions that
a number of genes are probably affected by spli-
ceopathy in DM1, including tau, amyloid precur-
sor protein (APP), and N-methyl-D-aspartate re-
ceptor 1 (NMDAR1).83 In addition, other genes
such as the dystrophia myotonica-containing WD
repeat motif (DMWD) clustered in the DMPK
gene region may also be implicated in brain-re-
lated symptoms,129 and this too requires further
investigation. (2) The existence of a juvenile form
of DM2 is yet to be described. (3) There are
unique features at the DM1 locus that account for
the congenital form, irrespective of repeat size.
In this review we focus on the similarities and
differences in brain involvement between DM1 and
DM2, with particular emphasis on the central ner-
vous system (CNS) characteristics of the adult forms
and on therapeutic and management problems.
EVIDENCE FOR BRAIN INVOLVEMENT IN DM1
Clinical Evidence. The occurrence of mental retar-
dation in the congenital form and behavioral abnor-
malities in the juvenile form is unquestionable. In
such patients the brain is undoubtedly involved pri-
marily in the disease process.
Congenital DM1. Congenital DM1 is associated
with (CTG)n expansions greater than 1,000. It oc-
curs in the offspring of mothers affected with myo-
tonic dystrophy.120 Congenital myotonic dystrophy is
the most severe presentation of DM1, not only from
a muscle and respiratory perspective, but also be-
cause of the degree of cognitive involvement. In
contrast with the classic adult form, neuromuscular
involvement and arrhythmias are not a major con-
cern. Myotonia is not even present at birth and
cardiovascular involvement is not a common prob-
lem.41
Onset is in the prenatal period. In almost half of
the pregnancies reported, fetal movements are re-
duced and polyhydramnios occurs.41 A small per-
centage of premature births occur. After birth, one
prominent sign is delay in motor milestones. Hypo-
tonia results in a ﬂoppy baby and immobility. Failure
to thrive is due to an inability to suck that affects
almost all patients as a result of bilateral facial and
jaw muscle weakness.41,107 This is typically present at
birth, giving rise to a characteristic facial appear-
ance: the newborn baby keeps the mouth open with
a tented upper lip and a high-arched palate. Respi-
ratory distress may be the presenting symptom in up
to 50% of patients.40,41 This is the result of different
factors including intercostal and diaphragmatic mus-
cle weakness, pulmonary immaturity, aspiration
pneumonia, and failure of respiratory control.103 In
nearly half of the reported cases talipes is present,
most often bilateral and in the equinovarus position.
Contractures may be present and athrogryposis mul-
tiplex may be an associated ﬁnding.41,107 Other dys-
morphic features and organ malformations may be
present. There is no clinical or electromyographic
(EMG) myotonia. Tendon reﬂexes are usually ab-
sent.
As time passes muscle symptoms improve but the
delayed motor development becomes prominent,
closely paralleling the degree of hypotonia. In those
patients who survive the early weeks of life the prog-
nosis is one of steady improvement throughout early
childhood. Almost all children eventually become
able to walk independently.
Mental retardation is observed in a number of
patients and does not parallel motor retardation.
Intelligence quotient (IQ) levels varying between 40
and 80 are present in 50%–90% of patients. Regard-
less, patients are able to take care of themselves
throughout adult life with no evidence of a gross
deterioration in intellectual function.41 Speech de-
velopment is delayed because of hypotonia and the
weakness of facial and jaw muscles as well as by
delayed psychomotor learning abilities. Behavioral
abnormalities such as hyperactivity attention deﬁcit,
autistic behavior, and difﬁculty in social relation-
ships with peers and family members are frequently
reported in the preschool age group.113 Neuroimag-
ing studies in these patients reveal ventricular dila-
tation in more than 50% of patients, which is present
at birth, thus supporting a prenatal origin for the
mental retardation.53
The congenital form differs from the classic form
not only clinically, but also from a biomolecular
view. Speciﬁcally, there are several distinct features
in congenital DM. The ﬁrst is aberrant methylation
at the DM1 locus.30,112 Dinucleotide CpGs in the
region of the CTG repeat are aberrantly methylated
only in congenital DM.112 The second is that in-
creased levels of DMPK transcripts have been found
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in the congenital form, whereas in the adult form
these levels are typically decreased.34,104 Congenital
myotonic dystrophy is only transmitted by affected
mothers and there is a suggestion of maternal im-
printing; paternally transmitted cases do not occur
even if the CTG repeats are similar in size.13
Childhood and Juvenile Onset. In DM1 a child-
hood or juvenile onset implies a different clinical
presentation than in the classic adult form. In the
juvenile form, CNS symptoms predominate over
muscle symptoms.
Unlike the congenital form, transmission is ma-
ternal or paternal. Symptoms are present in child-
hood before the age of 10, and there are usually no
prenatal signs. Motor symptoms are typically mild,
and motor development is usually normal or delayed
only slightly. There may be some degree of distal
weakness and atrophy as in the classic adult form, as
well as mild signs of clinical myotonia.40,41 The major
features, however, are behavioral and there is usually
a paucity of neuromuscular or cardiorespiratory
symptoms. Learning disabilities and difﬁculties in
relationships with peers generally become evident
during school age. Cognitive impairment has been
reported with IQ below normal for age.41,113,125 Chil-
dren may require teacher assistance and manifest
autistic behavior, lack of interest, and inhibition that
link to the adult-onset dysexecutive syndrome. Atten-
tional deﬁcit hyperactive disorder is frequent and is
often diagnosed in preschool children, before evolv-
ing into anxiety disorders in childhood and young
adulthood. Excessive daytime sleepiness and fatigue
may be present in this form as in the classic adult
form,93,113 suggesting that complaints of fatigue and
somnolence should be investigated by polysomnog-
raphy to look for sleep apnea syndrome and periodic
limb movements.
Conventional neuroimaging is often normal but
quantitative studies on a large number of patients
are lacking. There may be ventricular dilatation and
sulcal enlargement but, unlike the congenital form,
these are not prominent. The white matter hyperin-
tense lesions that are seen in the adult form are
infrequent.27,41
Adult-Onset DM1. More than 50% of patients
with classic DM1 are referred because of excessive
daytime sleepiness55,90,102 or fatigue.49 Patients usu-
ally minimize their symptoms, do not keep outpa-
tient appointments, and seem unconcerned about
their health. The general clinical impression in most
cases is one of apathy, decreased emotional partici-
pation, and psychomotor delay.
The result of neuropsychological tests provides
some evidence for this. Neuropathology and neuro-
imaging studies provide further support for the clin-
ical impression of brain involvement in the classic
adult form of DM1 (Table 1).
Neuropsychological Evidence. Global Intelligence.
Patients may give the impression of having reduced
overall intelligence because of the delay in motor
responses related to muscle impairment, the facial
expression resulting from bilateral ptosis and facial
muscle weakness, and the lack of initiative that may
predominate during an examination. Scores on
overall IQ as measured by the Wechsler Adult Intel-
ligence Scale (WAIS) are within the normal range in
patients with DM1,11,15,20,87,91,122,132,134 although
lower than age- and education-matched controls. In
a subset of patients with moderately severe DM1
(CTG range 500–700), we have found reduced IQ
values in one-third of patients irrespective of the
degree of muscle disability.
On Mini Mental State Examination (MMSE),
scores are also within the normal range, although
lower than age- and education-matched con-
trols.71,72,78
These studies, although interesting, are limited
by methodological restrictions and especially by the
variability in disability range and the molecular sta-
tus of the patients considered. Whether measure-
ments of global intelligence correlate with CTG size
is a controversial issue. Some authors have
concluded that CTG size correlates with IQ or
MMSE scores and thus may be of predictive val-
ue,23,47,65,88,101,122 but others have not found any cor-
relation.71,72,78
Visual-Spatial Deﬁcits. Visual-spatial impairment
is appreciated when patients with DM1 are asked to
perform everyday tasks requiring the assembly of
elements (e.g., dice, puzzles, or similar things), to
draw two-dimensional (2D) or three-dimensional
(3D) ﬁgures, or to make a spontaneous drawing of a
single ﬁgure. Patients may then admit to having
decreased ability to draw 2D or 3D shapes and ﬁg-
ures or to join up elements of a ﬁgure to form a
complete ﬁgure. There may be impairment in spatial
orientation as shown by map reading, target reach-
ing on a speciﬁc trajectory through the quickest
route, or constructional ability. Solving maze-like
problems may constitute a limitation. In the work-
place, visual-spatial impairment may translate into a
certain difﬁculty in aligning numbers in the correct
rows and putting items in appropriate columns.
From a neuropsychological perspective, visual-spatial
deﬁcits are detected when patients are asked to copy
a complex ﬁgure while maintaining its correct inter-
sections and angles (Rey copy and recall). There is
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general agreement that patients with DM1 present
deﬁcits in visual-spatial performance14,37,71,125 be-
cause their scores on neuropsychological tests are
signiﬁcantly lower than in age- and education-
matched controls. Modoni et al.78 strengthened this
conclusion in a recent study performed on a larger
sample of patients stratiﬁed by CTG size and dem-
onstrated that, despite small expansions, visual-
spatial deﬁcits characterize the neuropsychological
proﬁle of adult patients with DM1 in contrast with
the more general intellectual impairment of patients
with congenital forms.
Attentional Deﬁcits. Several investigators have de-
scribed attention deﬁcits assessed by neuropsycho-
logical test scores as below the normal range com-
pared to normal controls.78,133 In our experience, a
signiﬁcant difference was observed in test scores for
attention ability between patients with moderately
severe DM1 and controls.72
Verbal Fluency. Weakness of facial, jaw, and pal-
atal muscles, often in combination, results in a
speech disturbance that may be a concern for the
patients and family owing to the resulting difﬁculties
in communication. Additional factors may also ag-
gravate speech production, such as tongue and jaw
muscle myotonia and structural malformations such
as jaw subluxation and malocclusion, which are
present more frequently than in the general popu-
lation. Despite these peripheral causes of speech
dysfunction, language function seems to be normal
in patients with adult DM1. Normal performance on
verbal function tests in patients with DM1 using the
Token Test and the Controlled Association Letters
and Categories Test has been described.71,72
Behavior. Dysexecutive Syndrome. Reduced initia-
tive and inactivity are to be expected in any chronic
muscle disease. However, clinical experience sug-
gests that this is a prominent and consistent ﬁnding
in patients with DM1 as compared to patients with
other muscular dystrophies and similar or even
worse muscle weakness and functional limitations.
Frontal lobe motor areas and the prefrontal cortex
are involved in strategic planning tasks. Earlier re-
ports had documented a signiﬁcant impairment of
frontal lobe function,14,24 as is typical of a dysexecu-
tive syndrome. Several authors tried to correlate
neuropsychological and neuroimaging ﬁnd-
ings.6,24,27,28,45,62,101 Meola et al.71,72 conﬁrmed a se-
lective impairment on tests of frontal lobe function
in DM1 and suggested that this type of deﬁcit does
not correlate with cortical atrophy and white matter
hyperintense lesions, but might be associated with
fronto-temporal lobe hypoperfusion on PET studies.
Although interesting, these studies were limited by
the lack of quantitative magnetic resonance imaging
(MRI) studies. Other studies have conﬁrmed a selec-
tive involvement of frontal lobe function.13,36
Apathy. Apathetic temperaments are often re-
ported by family members of patients with DM1. It is
another aspect of the frontal dysexecutive syndrome
reported above. Rubinsztein et al.102 applied a spe-
ciﬁc rating scale for apathy and demonstrated that
apathy was signiﬁcantly greater in patients with DM1
than in normal controls or patients with Charcot–
Marie–Tooth disease. This was not related to the
degree of muscle impairment or the duration of
illness.
Anxiety. There are conﬂicting data as to the
occurrence of anxiety in DM1,10,20,22 although there
are suggestions that DSM-IVR Axis I disorders are
frequent in DM1 as in the general population.41
Meola et al.71 demonstrated that anxiety was not a
feature of a subset of patients with DM1 subjected to
a battery of neuropsychological tests and psychiatric
interviews. They concluded that the abnormal per-
formance found after speciﬁc tests for frontal lobe
function could not be attributed to anxiety or similar
affective disturbances.
Depression. Depression does not seem to be in-
creased in patients with myotonic dystrophy com-
pared to other patients with muscular dystrophies,29
although some reports describe a higher frequency
in DM1.22 Meola et al.71 investigated patients with
DM1 and did not ﬁnd a higher frequency of depres-
sion.
Personality Patterns. Whether patients with
DM1 have speciﬁc personality patterns is debat-
able.7,12,26,33,72 It is common clinical experience that
patients with DM1 have characteristic personalities:
they tend to be either obsessive in their health-
related care, continuously consulting their referring
physician, or avoidant and passive in their attitudes
toward health care. In an initial study by Bird et al.,7
one third of a small series of patients had prominent
abnormalities, but these were considered to be the
natural consequence of their motor and cognitive
impairment. In a later study, Delaporte26 described a
speciﬁc personality pattern in patients with DM1.
Obsessive-compulsive, avoidant, and passive-aggres-
sive behavior were prominent in these patients.
More recently, Meola et al.71 conﬁrmed these results
and suggested that there may be a homogeneous
avoidant personality proﬁle in patients with DM1. In
a minority of patients tested by Delaporte26 but in
none of those tested by Meola et al.,71 the scores
reached a pathological level for personality disorder.
Winblad et al.133 applied the Temperament and
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Character Inventory to patients with DM1 and com-
pared the results with those of patients with other
neuromuscular disorders, again emphasizing that
their DM1 patients had a deviant personality regard-
ing temperament and character; signs of personality
disorder were found in 20% of patients. In all of
these studies the personality proﬁle did not correlate
with the degree of muscle impairment or CTG ex-
pansion size.
Emotion. Winblad et al.131 demonstrated that fa-
cial emotion recognition is also impaired in patients
with DM1, the ﬁndings correlating with CTG size.
This impairment correlated only mildly with scores
on tests of frontal lobe function, suggesting that
mechanisms other than cognitive ability are in-
volved.
Somnolence. Excessive daytime sleepiness is a
prominent complaint made by partners and relatives
of patients with DM1,55,90,102 but the patients seem to
minimize the problem for unclear reasons that may
relate to their global cognitive and behavioral pro-
ﬁle. This attitude may explain why the Epworth
Sleep Scale often underestimates excessive daytime
sleepiness in patients with DM1.56 In patients with
end-stage disease, degeneration of oropharyngeal,
intercostals, and diaphragm muscles may lead to
obstructive sleep apnea and nocturnal alveolar hy-
poventilation.18,19 There is evidence that excessive
daytime sleepiness in DM1 is not the result of sleep
apnea124 but may result from direct involvement of
bulbar neurons in the reticular formation of the
brainstem.81,82 Broughton et al.10 concluded that
cognitive impairment cannot be attributed to a sec-
ondary effect of nocturnal sleep apnea or sleep dis-
turbance in patients with DM1, but probably repre-
sents a direct effect of CNS lesions. It is interesting to
consider that hereditary canine narcolepsy is caused
by mutations in the hypocretin receptor 2 (HcrtR2)
gene that induces aberrant splicing of the HcrtR2
pre-mRNA, resulting in a truncated receptor.58 Re-
cent reports have demonstrated low levels of Hcrt1
in some patients with DM168 but how these ﬁndings
and whether receptor abnormalities relate to exces-
sive daytime sleepiness in DM1 is still unclear.
Fatigue. Fatigue is a prominent complaint in
patients with DM1. The degree of inactivity in pa-
tients with DM1 may go beyond the degree of objec-
tive muscle weakness. Kalkman et al.49 assessed the
prevalence of fatigue in patients with DM1 as com-
pared to patients affected by muscular dystrophies
with a similar degree of muscle impairment but no
cognitive involvement (such as facioscapular muscu-
lar dystrophy and hereditary motor and sensory neu-
ropathy type I). They concluded that patients with
Table 1. Summary of cognitive, behavioral, and neuropsychological evidence for brain involvement in DM1 and DM2.
DM1 DM2 References
Clinical presentations
Congenital onset   27, 40, 41, 103, 107, 113, 120,
Juvenile onset   40, 93, 113, 125
Adult onset   17, 41, 83, 94, 116, 117
Signs and symptoms of CNS involvement
Cognition
General intelligence
IQ   11, 15, 20, 87, 91, 122, 132, 134
MMSE   71, 72, 78
Visual spatial deﬁcits   14, 37, 71, 78, 125
Attentional deﬁcits   72, 78, 133
Verbal ﬂuency /  71, 72
Behavior
Dysexecutive syndrome   6, 14, 24, 27, 28, 45, 62, 101
Apathy   102
Anxiety  / 20, 22, 41, 71
Depression   22, 29, 71
Personality patterns
Avoidant   26, 71
Obsessive-compulsive   26, 33
Passive-aggressive   26, 33
Dependent   12
Emotion
Facial emotion recognition deﬁcit  ? 131
Excessive daytime sleepiness   10, 18, 19, 55, 56, 90,102, 124
Fatiguability  / 49
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myotonic dystrophy had signiﬁcantly higher scores
of severe fatigue, reported more problems with con-
centration, and had more difﬁculty in initiating and
planning than the other two groups. Factors related
to cognitive abnormalities may play a more promi-
nent role in patients with DM1.
Neuropathological Evidence. Cell Loss. Ono et al.81
reported cell loss in speciﬁc areas of the brain at
postmortem of patients with DM1, such as in the
dorsal raphe nucleus, superior central nucleus, dor-
sal and ventral medullary nuclei, and subtrigeminal
medullary nucleus. Cell loss was more prominent in
patients suffering from excessive daytime sleepiness
and hypoventilation so that primary degeneration of
speciﬁc brainstem nuclei was considered a possible
neuropathological correlate of the clinical ﬁndings.
Other authors77 have also reported neuronal loss in
the superﬁcial layer of the frontal, parietal, and oc-
cipital cortex as well as in the substantia nigra and
locus ceruleus. The patient described by Mizukami
et al.77 had extrapyramidal traits as well as behavioral
abnormalities such as hallucinations, indifference,
mental slowness, and visual cognitive impairment, so
that in this case also the neuropathological changes
correlate with the clinical ﬁndings. These and other
observations81,99 suggest that, in the brains of pa-
tients with DM1, cell loss of speciﬁc areas may occur
and contribute to the cognitive and behavioral ab-
normalities observed.
Neuronal Intranuclear Inclusions. Neuronal eosin-
ophilic inclusion bodies have been described in early
studies80 in a relatively large proportion of the tha-
lamic nuclei (up to 30%) of patients with DM1,
similar to ﬁndings in primary progressive neurode-
generative disorders. These observations were con-
ﬁrmed by other authors,86 although their clinical
signiﬁcance is still unclear. Not only the thalamus
but also the substantia nigra80 and caudate nucleus86
may be involved. More recently, immunostaining of
the inclusions has demonstrated that they are com-
posed of ubiquitin and microtubule-associated pro-
teins, thus creating the neuropathological substrate
for including myotonic dystrophies amongst the
neurodegenerative disorders.
Strong support for the hypothesis of neurode-
generation has come from the work of Thornton
and colleagues,48 who demonstrated in postmortem
brain slices from patients with DM1 that mutant
RNA accumulates as nuclear foci in speciﬁc brain
areas where muscleblind proteins are also seques-
tered, leading to deregulated alternative splicing in
neurons of speciﬁc gene proteins including tau (ex-
ons 2 and 10), amyloid precursor protein, APP
(exon 7), and N-methyl-D-aspartate receptor 1,
NMDAR1 (exon 5). The distribution of ribonuclear
inclusions was wide, involving all sectors of the hip-
pocampus, dentate gyrus, thalamus, substantia nigra,
and the brainstem tegmentum. The only exception
was the cerebellar cortex, where localization was
minimal. RNA foci were also detected in the subcor-
tical white matter and the corpus callosum. Whereas
in other neurodegenerative disorders characterized
by inclusion bodies the signiﬁcance of these is still
uncertain, the fact that ribonuclear inclusions in
muscle are directly involved in disease pathogenesis
raises the possibility that CNS symptoms may also be
the result of alternative splicing of speciﬁc brain
protein mRNAs.
Neuroﬁbrillary tangles of the type seen in Alzhei-
mer’s disease and other neurodegenerative disor-
ders have been demonstrated in DM1.85,126,135 The
main constituent of neuroﬁbrillary tangles is patho-
logic tau proteins, which are usually hyperphospho-
rylated and insoluble, phosphatase-resistant, and ag-
gregated. Vermersch et al.126 have demonstrated
speciﬁc tau variants in the brains of patients with
DM1 in the hippocampus, entorhinal cortex, and
most of the temporal areas. In contrast to the situa-
tion in Alzheimer’s disease, tau precipitates are not
linked to amyloid deposits. In light of the abnormal
posttranscriptional control of tau protein demon-
strated in recent studies of postmortem brain slices
from patients with DM1, and in vitro studies on
transgenic mice,48,83,109,110 it is conceivable that ab-
normal splicing gives rise to abnormal tau variants
that precipitate in speciﬁc brain areas and constitute
the neuroﬁbrillary tangles described. In vitro studies
have demonstrated that expanded CUG repeats dis-
turb tau phosphorylation in a speciﬁc cell line.42
Whether splicing alteration of tau transcripts in-
volves various factors needs further investigation.57
Whether the effects of this spliceopathy on tau tran-
scripts alone account for the neurodegenerative as-
pects of patients with DM1 requires further in-depth
molecular evidence.
Cerebrospinal Fluid Findings. No speciﬁc cere-
brospinal ﬂuid ﬁndings have been reported in pa-
tients with DM1. One report documented abnormal
protein content in a subset of patients with DM1,43
the signiﬁcance of which is unclear. More recently,
Martinez-Rodriguez et al.68 reported decreased
orexin-A levels in the cerebrospinal ﬂuid of 3 of 9
patients with DM1 affected by excessive daytime
sleepiness, thus suggesting analogies with the mech-
anisms involved in narcolepsy.
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Neuroimaging Evidence. CT Scans. The most fre-
quent ﬁnding is hyperostosis frontalis interna to-
gether with a more diffuse hyperostosis in the calvar-
ium. Avrahami et al.5 found signiﬁcant hyperostosis
in 17 of 24 patients studied and concluded that this
was independent of endocrine abnormalities such as
increased growth hormone secretion or abnormal
calcium metabolism, but rather might be the result
of brain atrophy; endocrine abnormalities have not
been excluded by other authors.98
Conventional MRI Studies. Several reports have
documented cortical atrophy and white matter hy-
perintense lesions15,24,27,28,45,52,72,76,79 in patients with
DM1. Fiorelli et al.31 documented an increased fre-
quency of subarachnoid cysts in DM1. Cortical atro-
phy is generally more prominent in the frontal and
temporal lobes, and white matter hyperintense le-
sions are usually diffuse in both hemispheres, single
or conﬂuent, and often asymmetric in appearance.
There has been inconsistency in interpreting these
white matter hyperintense lesions and no general
agreement as to their clinical relevance. Some au-
thors do not ﬁnd a clinical correlate to the neuro-
imaging proﬁle,14 whereas others ﬁnd a correlation
between neuropsychological data and the distribu-
tion and severity of white matter abnormali-
ties.24,45,111 We found no correlation between the
degree of cerebral involvement on traditional MRI
studies and cognitive and behavioral proﬁles.72
Other authors suggest an evolution of white matter
abnormalities during the disease.28
Quantitative MRI Studies. Kassubek et al.51 con-
ﬁrmed and extended the initial reports with tradi-
tional MRI, demonstrating that cortical brain atro-
phy occurs in both diseases but to a minor degree in
DM2 compared to DM1. Voxel-based morphometry
has been used by several authors to map cortical and
subcortical gray matter atrophy in DM1 even where
there were no or minimal abnormalities on tradi-
tional MRI studies.2,38,84 These studies conﬁrm that
regional neuronal loss occurs in the parietal and
frontal lobes and demonstrate that atrophy extends
to the superior and middle temporal gyrus and the
occipital lobes. Ota et al.84 demonstrated that large
CTG expansions correlated with small brain vol-
umes. The exact distribution of neuronal loss may
facilitate clinical and functional correlations with the
cognitive and behavioral changes observed in DM1.
Qualitative MRI Studies. Several authors have
demonstrated with diffusion tensor imaging that
there are diffuse microstructural changes even in
normal-appearing white matter on traditional MRI
studies, suggesting that these abnormalities play a
role in the wide range of CNS symptoms described in
DM1.36,114 Ota et al.84 demonstrated microstructural
changes in fractional anisotropy and diffusivity in the
corpus callosum subregions connecting to cortical
areas, especially motor ones.
PET Studies. PET studies72 have demonstrated
hypoperfusion of frontal and temporal lobes in pa-
tients with DM1 and to a minor degree in patients
with DM2. This regional hypoperfusion correlated
with the frontal dysexecutive syndrome demon-
strated on neuropsychological testing. Fiorelli et al.32
demonstrated that cortical glucose utilization de-
creased in 20% of patients with DM1 using 18F-
labeled 2-ﬂuoro-2-deoxy-D glucose (FDG) and dy-
namic PET.
Brain MR Spectroscopy. Neurochemical alter-
ations observed with proton magnetic spectroscopy
have been documented in patients with DM116 and
these were correlated with CTG size.
BRAIN INVOLVEMENT IN DM2
The adult presentation of DM2 usually occurs in the
3rd to 6th decade, later than the classic adult form of
DM1. There is remarkable clinical heterogeneity in
DM2 and high serum CK levels may be the sole
manifestation of the disease,70,74 but, in general, two
main clinical pictures of DM2 emerge. Homozygosity
for the DM2 expansion does not seem to alter the
disease phenotype as compared with the heterozy-
gous state.108 There is the proximal myotonic myop-
athy (PROMM) phenotype73,97 characterized by on-
set in the 3rd or 4th decade, proximal muscle
weakness (usually mild to moderate), mostly affect-
ing the pelvic girdle with little or no muscle atrophy,
and normal or increased deep tendon reﬂexes asso-
ciated with mild clinical myotonia. Early-onset irides-
cent posterior lens cataracts are usually present. In
addition to this classic form, there may be a distinct
clinical presentation of DM2, the proximal myotonic
dystrophy phenotype (PDM), ﬁrst described by Udd
et al.123 In this form, onset occurs at a later age and
is characterized by remarkable proximal muscle at-
rophy and weakness, often mimicking progressive
spinal muscular atrophy.100 Clinical myotonia may
be absent and early-onset cataracts are not as fre-
quent as in PROMM.70 In both presentations, brain
symptoms are not prominent. However, there is
some evidence from neuropsychological test scores,
psychiatric interviews, and neuroimaging data that
brain involvement may be present in DM2 as in the
adult form of DM1, although to a minor degree.
Neuropsychological Evidence. Cognition. The main
neuropsychological evidence of cognitive impair-
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ment in DM2 comes from the studies of Meola et
al.,71,72 although these are limited by small numbers
of patients. In general, IQ and MMSE scores were in
the normal range, whereas neuropsychological
scores were below normal for age- and education-
matched controls on tests for visual-spatial perfor-
mance and attention, a situation similar to that in
DM1 patients, but milder. Regarding verbal ﬂuency,
patients with DM2, like those with DM1, do not
display lexical impairment on clinical examination
and, in agreement with the clinical impression, have
normal verbal ﬂuency.71,72 This is in contrast with
ﬁndings of Gaul et al.37 that DM1 and DM2 patients
scored lower than controls with respect to lexical
verbal ﬂuency.
Behavior. Evidence for some degree of behav-
ioral abnormalities in DM2, similar to those de-
scribed in DM1, comes from studies on a small num-
ber of patients.71,72 As in patients with DM1, the
main clinical ﬁnding suggesting behavioral abnor-
malities comes from tests of frontal lobe function,
suggesting a dysexecutive syndrome. As in DM1, ab-
normal scores on tests of frontal lobe function did
not correlate with cortical atrophy and white matter
hyperintense lesions but rather were associated with
fronto-temporal lobe hypoperfusion as documented
by PET studies. These studies were limited by the
lack of quantitative MRI studies. There was no evi-
dence in these studies that anxiety or depression
were a characteristic ﬁnding of patients with DM2.
Meola et al.71 found a homogeneous avoidant per-
sonality proﬁle in patients with DM2 as in DM1.
Somnolence. The degree of this complaint and
frequency in DM2 has not been investigated in de-
tail. In our experience, there is a subset of patients in
whom this complaint is prominent and cases of cen-
tral sleep apnea have been demonstrated, but less
frequently in DM2 than DM1.
Fatigue. There are no reports on the prevalence
and relevance of fatigue in patients with DM2, but
this does not seem to be a prominent feature in
these patients except for those with severe lower-
limb muscle weakness or muscle pain and locking.
Neuropathological Evidence. There is limited neuro-
pathological data for DM2. Maurage et al.69 sug-
gested that a similar brain tau pathology is found in
DM2 as in DM1, but further studies and evidence at
a molecular level are needed.
Neuroimaging Evidence. Conventional and Quantita-
tive MRI Studies. The ﬁrst reports of CNS involve-
ment on neuroimaging in DM2 came from Hund et
al.46 using conventional MRI studies. They described
a subset of patients with diffuse and conﬂuent white
matter hyperintense lesions similar to those found in
CADASIL. There was no apparent link to neuropsy-
chological abnormalities, but these were not ex-
plored in detail in the initial description. Other
studies52,71,72 followed, demonstrating that brain at-
rophy and white matter hyperintense lesions are
found in DM2 just as in DM1, but the severity of
white matter involvement described by Hund et al.
remained an isolated ﬁnding. These initial studies
were limited by the lack of quantitative MRI studies.
More recently, Kassubek et al.51 conﬁrmed and ex-
tended the initial reports with traditional MRI in
DM2,72 demonstrating that cortical brain atrophy
occurs in both diseases but to a lesser degree in DM2
than DM1.
Brain MR Spectroscopy. Recent studies127 suggest
that, although structural abnormalities may occur in
patients with DM1 and DM2, changes in cerebral
metabolites can differentiate these disease groups.
Further studies are needed to clarify whether this
difference accounts for involvement of different
neuropathological pathways in the two disorders.
PET Studies. PET studies72 have demonstrated
mild hypoperfusion of the frontal and temporal
lobes in patients with DM2 as in patients with DM1.
Sansone et al.105 studied one DM2 patient with
camptocormia using PET. Mesotemporal glucose
was reduced but the DOPA pathway was normal,
suggesting that the extrapyramidal signs encoun-
tered in this patient involved different pathways and
pathomechanisms than those of Parkinson’s disease,
and emphasize the clinical heterogeneity of DM2.
MULTIORGAN INVOLVEMENT AND COGNITIVE
FUNCTION
Cardiac conduction arrhythmias and cardiomyopa-
thy together with respiratory insufﬁciency frequently
present in these patients and contribute to the gen-
eral hypoperfusion and hypoxia of brain structures,
aggravating the cognitive and behavioral features
described.
Insulin resistance may play a role in aggravating
brain function. Brain metabolism accounts for 50%
of total body glucose utilization. The brain depends
on glucose as an energy substrate, with most brain
insulin coming from the pancreas, whence it is taken
up by the brain via a receptor-based carrier similar to
those demonstrated in muscle. Animal models of
type 2 diabetes associated with insulin resistance
show reduced insulin brain uptake and content.
There are suggestions that brain insulin receptors
may become less sensitive to insulin, and this could
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reduce synaptic plasticity.75 In addition, there is
some indication from animal models that reduced
sensitivity to insulin in the brain, as observed in
aging, decreases the clearance of abeta amyloid, thus
increasing amyloid toxicity. These fascinating obser-
vations are limited to animal models of type 2 dia-
betes, and caution is needed in interpreting these
ﬁndings; however, these preliminary suggestions
may provide some indirect speculative evidence that
glucose metabolism abnormalities such as those ob-
served in DM might inﬂuence brain symptoms.
CLINICAL RELEVANCE OF BRAIN INVOLVEMENT
IN DM
Although cognition in terms of overall intelligence
may not be impaired, lack of initiative, inactivity, and
apathetic attitudes constituting the cardinal feature
of the dysexecutive syndrome are all characteristic of
DM patients. In clinical practice this represents a
limitation because patients may be passive in their
health-related care, may miss outpatient visits, and
may not attach any importance to certain symptoms.
Family members, relatives, and possibly even employ-
ers need to be aware of these aspects because inac-
tivity may be related to CNS dysfunction rather than
muscle disability.
Excessive daytime sleepiness is a prominent fea-
ture that may interfere with daily and work-related
activities. This is often underestimated by patients
and should be sought by asking family members and
relatives. Deviant personalities are another charac-
teristic of patients with DM1 and DM2. Obsessive-
compulsive, passive, or avoidant traits may dominate
the clinical picture and limit patients’ relationships
and everyday activities. This knowledge is important
to clinicians and relatives in order to improve the
approach to these patients, who may require more
time and persuasion if they are to overcome their
obsessive, passive, or avoidant personality traits.
Although no speciﬁc therapeutic agents are cur-
rently available to inﬂuence CNS symptoms,1,115 and
while awaiting drugs that may revert abnormal splic-
ing of brain gene proteins or replace MBNL deple-
tion,21,50 awareness of the frequent occurrence of
CNS symptoms even in the adult form of myotonic
dystrophy is helpful. It may help physicians, family
members, and employers to understand why, despite
mild muscle disability, patients with DM may not
function as well as expected by their muscle strength
and status. These aspects should be taken into ac-
count when planning a clinical trial. Measures of
cognitive and behavioral involvement should be in-
cluded to assess the efﬁcacy of treatment. If the
target is muscle, strength may improve, but if inac-
tivity related to the dysexecutive syndrome is unaf-
fected the results of a treatment may be underesti-
mated.
As to the psychosocial aspects, Prevost et al.92
have said that predictive testing for DM1 was per-
ceived as a change for the worse by many DM1
carriers, suggesting that despite the apparently ap-
athic attitudes and reduced ability to capture emo-
tion by facial expression, the disease represents an
emotional burden for these patients.
In general, patients and relatives should be reas-
sured about the degree of brain involvement. If pa-
tients with the congenital form survive the initial
phases of respiratory distress, the outcome in gen-
eral is one of gradual improvement, especially with
adequate family and psychosocial support.
There are suggestions3 that health-related quality
of life assessed by short form 36 item health status
survey (SF-36) is severely impaired in patients with
DM1 and that it is negatively inﬂuenced by the se-
verity and duration of the disease as well as by spe-
ciﬁc cognitive deﬁcits such as visual-spatial and ver-
bal-abstract reasoning. Emphasis on these ﬁndings
may target therapeutic strategies that could improve
the quality of life for these patients.
There are limited studies on the progression of
cognitive decline over time121,130 and whether the
brain abnormalities described so far in patients with
DM1, and to a lesser degree in patients with DM2,
culminate in a dementia syndrome is yet to be dem-
onstrated. We have followed a small group of pa-
tients with DM1 and DM2 over a mean follow-up
period of about 8 years, and observed that there was
worsening of neuropsychological test scores over
time, but no extension to additional areas of cogni-
tion or interference with everyday activities.106 These
observations, although they relate to only a small
group of patients, may have important prognostic
implications.
Finally, we can conclude that signs of CNS in-
volvement (inactivity, decreased initiative, memory
deﬁcits, and visual-spatial abnormalities) together
with multiple organ degeneration contribute, at
least in part, to premature aging in patients with
myotonic dystrophies so that DM1 has, in fact, been
considered a possible segmental progeroid syn-
drome.128 The exact mechanisms of premature ag-
ing in DM1, at least, may in part be related to in-
creasing (CTG)n repeat lengths with age.39 Future
treatments that revert abnormal brain gene protein
splicing may maintain proper protein processing
and folding, thus representing a partial antidote to
302 Brain in Myotonic Dystrophies MUSCLE & NERVE September 2007
premature aging in DM1 through genetic modula-
tion.67
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